Wuhan BravoVax Co., Ltd (BravoVax) is a "state level high-tech enterprise" established in the year 2012 and is specialized in the R&D, manufacturing and marketing of high-end human vaccines. BravoVax is committed to the R&D and industrialization of a number of blockbuster vaccines such as novel COVID-19 Vaccine, multivalent Rotavirus Vaccine, next-generation Pneumococcal Conjugate Vaccine, broad-spectrum Human Papillomavirus (HPV) Vaccine and Recombinant Varicella-zoster Virus (HZV) Vaccine. As one of active members in Developing Countries Vaccine Manufacturers Network (DCVMN) and a council number of China Association for Vaccines (CAV), BravoVax will gradually push these products into the market in accordance to China cGMP, WHO cGMP and IHC guidance, meeting the vaccine demands in domestic and global markets, and benefiting the whole society.